Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Medical Oncology
Would you start immunotherapy in a patient with metastatic melanoma who is on steroids (e.g. dexamethasone for cerebral edema)?
Or would you try to wait and get the steroids off first?
Answer from: Medical Oncologist at Academic Institution
In general immunotherapy should not be started if patients require predisone or the equivalent more than 10 mg a day.
Sign in or Register to read more
2357
Related Questions
How should the use of the DecisionDx-Melanoma test be integrated into clinical practice to potentially avoid sentinel lymph node biopsy?
What is the optimal approach to managing oral toxicities, such as dysgeusia, caused by immune checkpoint inhibitors (ICIs)?
In what situations would you recommend adjuvant radiation therapy for patients with locally advanced and/or recurrent basal cell carcinoma that receive vismodegib followed by surgery?
Do you obtain MRI for cutaneous SCC with microscopic PNI to assess for gross perineural tumor spread?
How do you approach the management of patients with locally advanced unresectable mucosal melanoma in the head and neck region?
How do you manage new-onset vitiligo in a patient on immune checkpoint inhibitors?
How would you approach management of a large, fungating squamous cell carcinoma of the auricle if surgical management is not desired by the patient?
What is the current role of ctDNA in guiding the selection of adjuvant treatment for stage II-IIIA melanoma?
Would you consider proceeding with a sentinel lymph node biopsy after wide excision revealed 1.2 mm residual non-ulcerated T2a melanoma on the upper back?
How, if at all, are you modifying your practice and clinical workflow for patients receiving checkpoint inhibitors with data showing improved outcomes for patients receiving infusions earlier in the day?